{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:25:30Z","timestamp":1790227530304,"version":"4.1.0"},"reference-count":69,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orthopedics"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>\n            Denosumab, a human monoclonal antibody that inhibits bone resorption by binding on the receptor activator of the nuclear factor kappa-\u03b2 ligand, has recently emerged as an additional option in the treatment of musculoskeletal osteolytic tumors. This article focuses on the recent literature regarding the effectiveness of denosumab in the management of giant cell tumor, multiple myeloma, aneurysmal bone cyst, and osteosarcoma. The mechanism of action of denosumab in the management of these tumors and the associated side effects are discussed in detail. [\n            <jats:italic>Orthopedics.<\/jats:italic>\n            2017; 40(4):204\u2013210.]\n          <\/jats:p>","DOI":"10.3928\/01477447-20170627-04","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T13:15:29Z","timestamp":1503494129000},"page":"204-210","source":"Crossref","is-referenced-by-count":28,"title":["Denosumab: Current Use in the Treatment of Primary Bone Tumors"],"prefix":"10.3928","volume":"40","author":[{"given":"Olga D.","family":"Savvidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna K.","family":"Bolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Chloros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Koutsouradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis J.","family":"Papagelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2160"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000098223"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1199"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2684"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-010-0812-3"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0154"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/46303"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.1.192"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"issue":"2","key":"e_1_3_1_11_2","first-page":"83","article-title":"Recent advances in bone biology provide insight into the pathogenesis of bone diseases","volume":"79","author":"Boyce BF","year":"1999","unstructured":"Boyce BF, Hughes DE, Wright KR, Xing L, Dai A. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest. 1999; 79(2):83\u201394.","journal-title":"Lab Invest"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11685"},{"issue":"9","key":"e_1_3_1_13_2","first-page":"2096","article-title":"Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice","volume":"63","author":"Yonou H","year":"2003","unstructured":"Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice. Cancer Res. 2003; 63(9):2096\u20132102.","journal-title":"Cancer Res"},{"issue":"4","key":"e_1_3_1_14_2","first-page":"627","article-title":"Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases [in Japanese]","volume":"16","author":"Dougall W","year":"2006","unstructured":"Dougall W, Chaisson M. Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases [in Japanese]. Clin Calcium. 2006; 16(4):627\u2013635.","journal-title":"Clin Calcium"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154680"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2171"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000195089.11620.b7"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocl.2005.08.005"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200204000-00029"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-007-0310-x"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1148\/rg.331125089"},{"issue":"9","key":"e_1_3_1_22_2","first-page":"3795","article-title":"Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence","volume":"30","author":"Kafchitsas K","year":"2010","unstructured":"Kafchitsas K, Habermann B, Proschek D, Kurth A, Eberhardt C. Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence. Anticancer Res. 2010; 30(9):3795\u20133799.","journal-title":"Anticancer Res"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10258"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e3283463536"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2013.49.11.2064725"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-010-1501-7"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1497"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.94"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/03008207.2013.848202"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0432"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-016-0123-0"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0578"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-1034-y"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad0295"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000506"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148401"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203248"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1278305"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv307"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aott.2016.03.004"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.12.002"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.336"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.004"},{"issue":"11","key":"e_1_3_1_46_2","first-page":"2271","article-title":"Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab","volume":"55","author":"Tatekoshi A","year":"2014","unstructured":"Tatekoshi A, Sato T, Ibata S, et al. Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab. Rinsho Ketsueki. 2014; 55(11):2271\u20132276.","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.96"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-17"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000001818"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/01202412-200411000-00008"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-198603000-00003"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.175133"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-013-2715-7"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000001027"},{"issue":"17","key":"e_1_3_1_55_2","first-page":"3692","article-title":"Denosumab: non-surgical treatment option for selective arterial embolization resistant aneurysmal bone cyst of the spine and sacrum: case report","volume":"20","author":"Ghermandi R","year":"2016","unstructured":"Ghermandi R, Terzi S, Gasbarrini A, Boriani S. Denosumab: non-surgical treatment option for selective arterial embolization resistant aneurysmal bone cyst of the spine and sacrum: case report. Eur Rev Med Pharmacol Sci. 2016; 20(17):3692\u20133695.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2015.06.002"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.9.1766"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1159\/000369975"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2142-2"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.12968\/denu.2015.42.5.436"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2015.12.005"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61338-6"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2016.1277412"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12517"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.01.005"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.05.016"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25393"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0677-z"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/767198"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000165"}],"container-title":["Orthopedics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/orthopedics\/journals\/ortho\/2017-7-40-4\/%7B797dbdc1-5ebb-4f1f-8d9b-8815605bb0d6%7D\/denosumab-current-use-in-the-treatment-of-primary-bone-tumors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T22:22:36Z","timestamp":1683066156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/01477447-20170627-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.3928\/01477447-20170627-04"],"URL":"https:\/\/doi.org\/10.3928\/01477447-20170627-04","relation":{},"ISSN":["0147-7447","1938-2367"],"issn-type":[{"value":"0147-7447","type":"print"},{"value":"1938-2367","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}